Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Novartis Sells Shares Back to Roche for $20.7 Billion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 04, 2021 1:46pm

172 Views

Post# 34087735

RE:Novartis Sells Shares Back to Roche for $20.7 Billion

The deal extricates Roche from ownership ties to a major competitor with strategic vetoing power.

Roche said it will use debt to finance what it called a "disentanglement of two competitors" and plans to reduce its capital by cancelling the repurchased shares to regain full strategic flexibility.

The transaction sent Roche shares to a record high. By mid-morning, they were up 2.4%, while Novartis shares were up 0.2%.

<< Previous

Bullboard Posts

Next >>

Boeing workers end strike, return to work